In this guest column, Scott Mazza examines emerging peer-reviewed research supporting the cannabis “entourage effect,” arguing that cannabinoids, terpenes, and flavonoids interact synergistically to influence therapeutic outcomes beyond isolated compounds alone. Citing findings published in Molecules, the article explains how these interactions may shape analgesic, anti-inflammatory, and neuroprotective effects, while also highlighting the need for further research to clarify compound-specific contributions. Mazza situates these findings within a broader shift toward whole-plant and chemistry-driven approaches to cannabis formulation, treatment, and classification.

Scott Mazza examines the hemp industry’s leading regulatory priorities ahead of the upcoming Farm Bill, including classifying CBD as a conventional dietary supplement and food ingredient, easing testing bottlenecks, and adjusting federal THC limits for hemp. Drawing on current FDA, USDA, and industry positions, the article argues that existing regulatory frameworks can address safety and quality concerns without creating new, uncertain pathways. The piece frames these proposals as pragmatic, farmer-focused adjustments aimed at stabilizing the CBD market and providing clearer federal guidance.

In this article, Scott Mazza of Vitality CBD examines the role of flavonoids in shaping cannabis color, flavor, and aroma, alongside their lesser-known biological functions within the plant. The article explains how flavonoids interact with terpenes and cannabinoids as part of the entourage effect, potentially influencing therapeutic outcomes, particularly in full-spectrum formulations. Mazza also emphasizes the need for deeper research and informed consumer scrutiny, especially regarding product composition, testing standards, and claims around anxiety and other health applications.

In a guest column for NY Cannabis Insider, Scott Mazza explains how the one-year extension of the 2018 Farm Bill delays long-awaited clarity on CBD regulation and hemp-derived cannabinoids, including delta-8 THC, prolonging uncertainty for producers, consumers, and regulators. He outlines how the extension constrains industry planning and innovation while urging producers to rely on third-party testing, transparent labeling, and compliance with existing hemp thresholds to protect consumers during the interim. Mazza argues that clearer federal definitions and enforceable standards in Farm Bill 2024 are essential to stabilize the market, address emerging cannabinoid loopholes, and align regulation with growing scientific evidence and public acceptance.

In a commentary for Nutritional Outlook, Scott Mazza reviews 2023 as a year of regulatory stagnation but meaningful scientific and social progress for CBD, highlighting the delayed Farm Bill update, ongoing uncertainty around delta-8 THC, and FDA hesitation on CBD as a dietary supplement. He outlines key research milestones from the year, including emerging evidence on CBD’s role in opioid use disorder, dosage safety thresholds, hair loss, and other health conditions that continue to reshape the compound’s scientific credibility. Mazza concludes that declining social stigma and growing consumer adoption position CBD for further maturation in 2024, provided policymakers deliver clearer regulatory guidance and enforceable production standards.

In an article for NutraIngredients, Scott Mazza comments on the one-year extension of the 2018 Farm Bill, warning that the delay prolongs regulatory uncertainty around CBD and hemp-derived cannabinoids in the U.S. market. He explains that postponing Farm Bill reform leaves unresolved issues such as the legality of delta-8 THC, complicates long-term planning for producers, and slows innovation across the hemp industry. Mazza argues that clearer federal guidance is urgently needed to provide stability, protect consumers, and support sustainable growth while policymakers continue to debate the future regulatory framework.

In a guest column for NY Cannabis Insider, Scott Mazza analyzes new toxicology research that establishes evidence-based upper limits for daily CBD intake, moving the industry beyond informal dosage “guesstimates.” He highlights findings indicating that healthy adults can safely consume up to 160 mg of CBD per day, while lower limits apply to pregnant or breastfeeding individuals and those at risk of liver injury. Mazza argues that clearly defined dosage thresholds are a necessary step toward responsible regulation, informed consumer use, and the integration of CBD into mainstream health and wellness frameworks.

In a guest column for NY Cannabis Insider, Scott Mazza reviews emerging clinical evidence linking cannabis-based therapies to symptom relief in fibromyalgia, a chronic condition affecting millions of Americans with limited treatment options. He cites recent studies showing that THC- and cannabinoid-containing formulations were associated with statistically significant improvements in pain, depression, and quality of life, as well as reduced reliance on conventional medications. Mazza emphasizes that realizing this therapeutic potential will require more rigorous research alongside stricter industry standards for cannabinoid product purity, potency, and consistency to support medical use.

In an article for Nutritional Outlook, Scott Mazza examines emerging research suggesting that topical hemp formulations rich in cannabinoids, including CBD, may support hair regrowth and could offer an alternative or complement to conventional treatments like finasteride and minoxidil. He highlights findings from a small clinical case series reporting significant hair regrowth without adverse effects, while emphasizing that the mechanism of action appears distinct from existing therapies. Mazza cautions that meaningful progress in CBD-based hair health depends on stronger industry-wide standards for purity, potency, and labeling to ensure consumer safety and scientific credibility.

In an article for Cannabis & Tech Today, Scott Mazza argues that reclassifying cannabis from Schedule I to Schedule III would mark a pivotal shift in U.S. drug policy by reducing stigma, expanding access to scientific research, and aligning federal law with current medical evidence and public opinion. He highlights how rescheduling would ease restrictions on clinical trials, accelerate innovation in areas such as pain management and mental health, and improve access to banking and capital for cannabis businesses. Mazza concludes that grounding cannabis policy in data and science could deliver broad societal, economic, and research benefits while creating a more equitable regulatory environment for the industry.

In this article, Scott Mazza examines delta-8 THC as a hemp-derived cannabinoid operating in a legal gray area shaped by the 2018 Farm Bill, inconsistent state-level restrictions, and limited federal guidance. He explains how delta-8 is typically synthesized from hemp-derived CBD, why its psychoactive effects are often described as milder than delta-9 THC, and how regulatory gaps have contributed to quality, safety, and labeling concerns across the market. Mazza argues that clearer federal legislation and enforceable production standards are necessary to protect consumers, enable legitimate research, and bring regulatory certainty to the delta-8 category.

In this expert commentary for Cannabis Health, Scott Mazza, co-founder and COO of Vitality CBD, examines the growing use of CBD in fitness while cautioning athletes about industry-wide quality and safety risks. He outlines preclinical evidence supporting CBD’s potential role in inflammation reduction, recovery, mobility, and sleep, while emphasizing that poor testing standards and contamination remain significant concerns. The article underscores the need for transparent labeling, third-party testing, organic production, and careful dosing so athletes can use CBD responsibly and minimize avoidable risks.